
Commit Biologics
- Commit Biologics just raised $60M (Seed) on Nov 1
Developer of complement-powered immune engagers for cancer and autoimmune diseases.
About
Commit Biologics is a Danish biotechnology company developing a new class of immunotherapy treatments for cancer and autoimmune diseases. Using its proprietary Bispecific Complement Engager (BiCE) platform, the company designs complement-powered immune engagers that selectively eliminate diseased cells through complement activation without relying on T cells.
Where Commit Biologics is heading
Updated Nov 17, 2026, from 9 sources
Commit Biologics develops bispecific complement engagers, called BiCE, that direct the complement system to selectively destroy cancer and autoimmune disease cells without relying on T cells.commitbio.com Its two-year record shows a move from platform launch to clinical readiness, closing with its first development candidate named and a $60 million round raised.
commitbio.com
eu-startups.com
May 2024
Launched with €16 million in seed financing to develop the BiCE complement-engaging platform for cancer and autoimmune disease.
commitbio.com
Aug 2024
Raised a $17.3 million seed round.
commitbio.com
Jan 2025
Extended seed financing by €5.5 million and added an R&D-focused board executive.
commitbio.com
Nov 2025
Achieved proof-of-concept for the BiCE platform in non-human primates.
commitbio.com
Mar 2026
Appointed a serial biotech founder as CEO with a mandate to take complement-powered immune engagers into the clinic.
commitbio.com
Nov 2026
Named its first BiCE development candidate, strengthened senior leadership, and closed a $60 million seed round to fund clinical advancement.
commitbio.com
eu-startups.com
What it points to: The nomination of a first development candidate, a $60 million seed close, and a CEO hired specifically to take BiCE into the clinic point to Commit Biologics preparing to advance into human clinical trials.commitbio.com
eu-startups.com
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to Commit Biologics?
People comparing tools land here. Get listed beside these.
All funding rounds
Key facts
- Website
- commitbio.com
- Headquarters
- Copenhagen, Denmark
- Founded
- 2021
- Total funding
- $77M (Seed)
- Business model
- B2B
Funding rounds
- $60M1 Nov 2026SeedLargest round
- $17M22 Aug 2024
Led by Bioqube Ventures, Novo Holdings
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 1 Nov 2026 | Seed | $60M | |
| 22 Aug 2024 | Seed | $17M | Bioqube Ventures, Novo Holdings |
Tech stack
Detected on commitbio.com, last scanned 17 Nov 2026. Run your own scan
- Frontend
- jQuery
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Email provider
- Barracuda
Benchmarking
See how your site ranks against 16,849 startups
Commit Biologics sits in the 10th percentile for Domain Rating. Check where yours lands, free.
Check your Domain RatingCommit Biologics has a Domain Rating of 6, the 10th percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Bottom 25%
Check yoursAgent Readiness
Top 25%
Scan yoursSite Speed
Above median
PageSpeedData Trust
Above median
Security
Click to scan
Agent Readiness
Can AI agents use your site?
Commit Biologics scores 57. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentGet notified when Commit Biologics changes
Used Commit Biologics? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Is Commit Biologics growing?
Yes, fast. Our data shows it raised $60M in a Seed in November 2026, more than the $17M it raised in all the years before.
Who owns Commit Biologics?
Commit Biologics is privately held, owned by its founders and investors. Bioqube Ventures has backed 2 of the 2 rounds on record since August 2024, ahead of Novo Holdings (2), so it is likely among the largest outside shareholders. Exact stakes are not public.
Are there companies like Commit Biologics?
Yes. We list 7 companies like Commit Biologics, including Apellis Pharmaceuticals, Cue Biopharma and Tharimmune.
Is Commit Biologics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Commit Biologics is 62 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Commit Biologics raised?
Commit Biologics has raised a total of $77M in funding. The most recent round on record is Seed.
SEC filings, insider activity, nonprofit links and pay benchmarks for Commit Biologics:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch Commit Biologics and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini

